Comparison

GW6471 European Partner

Item no. S2798-10mM/1mL
Manufacturer Selleckchem
CASRN 880635-03-0
Amount 10 mM/1 mL
Quantity options 10 mg 1 g 10 g 10 mM/1 mL 50 mg 5 g
Category
Type Inhibitors
Specific against other
Smiles CCC(=O)NCC(CC1=CC=C(C=C1)OCCC2=C(OC(=N2)C3=CC=CC=C3)C)NC(=CC(=O)C4=CC=C(C=C4)C(F)(F)F)C
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Available
Storage Conditions
2 years -80 in solvent
Molecular Weight
619, 67
IC50
0.24 uM [1], 0.24 uM [1], 0.24 uM [1], 0.24 uM [1], 0.24 uM [1], 0.24 uM [1]
In vitro
GW6471 completely inhibits GW409544-induced activation of PPARalpha with IC50 of 0.24 uM. GW6471 at concentration ranging from 0.001-10 uM disrupts the interactions between PPAR and coactivator motifs derived from SRC-1 or CBP, but promotes the binding of the co-repressor motifs from SMRT or N-CoR. GW6471 adopts a U-shaped configuration and wraps around C276 of helix 3, destroys the integrity of the charge clamp but leaves sufficient space to accommodate the additional helical turn of the co-repressor motif in the PPAR/GW6471/SMRT complexes. [1] GW6471 at concentration of 10 uM significantly prevents cardiomyocyte differentiation and results in the reduced expression of cardiac sarcomeric proteins (ie alpha-actinin, troponin-T) and specific genes (ie alpha-MHC, MLC2v) in a time-dependent manner through inhibiting PPARalpha. [2]
Kinase Assay
Binding assays, The effects of GW6471 on the interaction of coactivator and co-repressor peptides with PPAR are determined by chemical-mediated fluorescence energy transfer assays. The experiments are conducted with 5 nM PPARalpha LBD of biotinylated peptide containing individual motifs , following the manufacturer's instructions for the hexahistidine detection kit in a buffer containing 50 mM MOPS, pH 7.4, 50 mM NaF, 0.05 mM CHAPS, 0.1 mg/mL bovine serum albumin, and 10 mM dithiothreitol (DTT). The binding signals are detected with the increasing concentrations of GW6471, and the results from four repeated experiments are normalized as a percentage of the binding in the absence of GW6471. The effects of GW6471 on the affinity of the SMRT or N-CoR peptides with purified PPAR LBD are determined by fluorescence polarization in a buffer containing 10 mM HEPES, pH 7.4, 0.15 M NaCl, 3 mM EDTA, 0.005% polysorbate-20, 5 mM DTT and 2.5% DMSO. Varied concentration of PPAR LBD in the presence or absence of 40 uM GW6471 are incubated at room temperature with 10 nM of a fluorescein-labelled peptide of N-CoR2 or SMRT2. The fluorescence polarization values for each concentration of receptor are determined using a BMG PolarStar Galaxy fluorescence reader with 485 nm excitation and 520 nm emission filters. The apparent dissociation constant (Kd) values are determined by the binding curves derived from a nonlinear least-squares-fit of the data for a simple 1:1 interaction.
Information
GW 6471 is a potent antagonist of PPARα with IC50 of 0.24 μM.
Chemical Name
(S, Z)-N-(3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(4-oxo-4-(4-(trifluoromethyl)phenyl)but-2-en-2-ylamino)propyl)propionamide

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 10 mM/1 mL
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?